COST-UTILITY ANALYSIS OF PERSONALIZED ANTIPLATELET THERAPY-Reference-Cited by-同舟云学术

COST-UTILITY ANALYSIS OF PERSONALIZED ANTIPLATELET THERAPY

Published:2023-05-24 Issue:1 Volume:4 Page:17-26
ISSN:2712-8164
Container-title:CASPIANJOURNALOF MEDICINE AND PHARMACY
language:en
Short-container-title:

Author:

Abdullaev Musalitdin¹,Kantemirova B.¹,Chernysheva Elena¹,Romanova Aleksandra

Affiliation:

1. Astrakhan State Medical University

Abstract

The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug prasugrel in slow and intermediate metabolizers (CUA: 289,111.00 rubles per QALY).

Publisher

Astrakhan State Medical University

Reference20 articles.

1. Sorich M. J., Rowland A., McKinnon R. A., Wiese M. D. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel : a meta-analysis // Circulation : cardiovascular genetics. 2014. Vol. 7, no. 6. P. 895–902. doi: 10.1161/CIRCGENETICS.114.000669., Sorich M. J., Rowland A., McKinnon R. A., Wiese M. D. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circulation: cardiovascular genetics. 2014; 7(6):895-902. doi: 10.1161/CIRCGENETICS.114.000669.

2. Joo H. J., Ahn S. G., Park J. H., Park J. Y., Hong S. J., Kim S. Y., Choi W., Gwon H., Lim Y. H., Kim W., Kang W. C., Cho Y. H., Kim Y. H., Yoon J., Shin W., Hong M. K., Garg S., Jang Y., Lim D. S. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention : a prospective multicentre registry study // Scientific reports. 2018. Vol. 8, no 1. P. 1-9. doi: 10.1038/s41598-017-18134-y., Joo H. J., Ahn S. G., Park J. H., Park J. Y., Hong S. J., Kim S. Y., Choi W., Gwon H., Lim Y. H., Kim W., Kang W. C., Cho Y. H., Kim Y. H., Yoon J., Shin W., Hong M. K., Garg S., Jang Y., Lim D. S. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study. Scientific reports. 2018; 8(1):1-9. doi: 10.1038/s41598-017-18134-y.

3. Xi Z., Fang F., Wang J., AlHelal J., Zhou Y., & Liu W. CYP2C19 genotype and adverse cardiovascular out-comes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis // Platelets. 2019. Vol. 30, no 2. P. 229–240. doi: 10.1080/09537104.2017.1413178., Xi Z., Fang F., Wang J., AlHelal J., Zhou Y., & Liu W. CYP2C19 genotype and adverse cardiovascular out-comes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis. Plate-lets. 2019; 30(2):229-240. doi: 10.1080/09537104.2017.1413178.

4. Lee C. R., Luzum J. A., Sangkuhl K., Gammal R. S., Sabatine M. S., Stein C. M., Kisor D. F., Limdi N. A., Lee Y. M., Scott S. A., Hulot J. S., Roden D. M., Gaedigk A., Caudle K. E., Klein T. E., Johnson J. A., Shuldiner A. R. Clinical Pharmacogenetics Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update // Clinical Pharmacology & Therapeutics. 2022. Vol. 112, no. 5. P. 959–967. doi: 10.1002/cpt.2526., Lee C. R., Luzum J. A., Sangkuhl K., Gammal R. S., Sabatine M. S., Stein C. M., Kisor D. F., Limdi N. A., Lee Y. M., Scott S. A., Hulot J. S., Roden D. M., Gaedigk A., Caudle K. E., Klein T. E., Johnson J. A., Shuldiner A. R. Clinical Pharmacogenetics Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics. 2022; 112(5):959-967. doi: 10.1002/cpt.2526.

5. Сычев Д. А., Шуев Г. Н., Торбенков Е. С., Адриянова М. А. Персонализированная медицина : взгляд клинического фармаколога // Consilium medicum. 2017. Т. 19, № 1. С. 61–68., Sychev D. A, Shuev G. N., Torbenkov E. S., Adrijanova M. A. Personalized medicine: clinical pharmacolo-gist’s opinion. Consilium Medicum. 2017; 19 (1): 61–68. (In Russ).